Kevin McCulloch - 13 Jun 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: President and Chief Operating Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 13 Jun 2025
Net transactions value: +$109,475
Form type: 4
Filing time: 16 Jun 2025, 16:26:02 UTC
Previous filing: 03 Apr 2025
Next filing: 04 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
McCulloch Kevin	President and Chief Operating Officer	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	16 Jun 2025	0002031695

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Purchase	$109,475	+25,000	+1.5%	$4.38	1,708,585	13 Jun 2025	Direct	F1
holding	XERS	Common Stock						25,000	13 Jun 2025	By Spouse	F2
holding	XERS	Common Stock						2,000	13 Jun 2025	By Charles R. McCulloch Trust dated 1990	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.3750 to $4.380, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2	The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.3750 to $4.380, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer